These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33363254)

  • 41. In Silico Evaluation of Sesquiterpenes and Benzoxazinoids Phytotoxins against M
    Mejías FJR; Durán AG; Chinchilla N; Varela RM; Álvarez JA; Molinillo JMG; García-Cozar F; Macías FA
    Toxins (Basel); 2022 Aug; 14(9):. PubMed ID: 36136537
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
    Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
    J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2.
    Pokhrel S; Bouback TA; Samad A; Nur SM; Alam R; Abdullah-Al-Mamun M; Nain Z; Imon RR; Talukder MEK; Tareq MMI; Hossen MS; Karpiński TM; Ahammad F; Qadri I; Rahman MS
    Int J Biol Macromol; 2021 Nov; 191():1114-1125. PubMed ID: 34592225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Homologous modeling and binding ability analysis of Spike protein after point mutation of severe acute respiratory syndrome coronavirus 2 to receptor proteins and potential antiviral drugs].
    Cao Z; Wang LT; Liu ZM
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 53(1):150-158. PubMed ID: 33550350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy.
    Wei TZ; Wang H; Wu XQ; Lu Y; Guan SH; Dong FQ; Dong CL; Zhu GL; Bao YZ; Zhang J; Wang GY; Li HY
    Chin J Integr Med; 2020 Sep; 26(9):663-669. PubMed ID: 32740825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of natural products to block SARS-CoV-2 S-protein interaction with Neuropilin-1 receptor: A molecular dynamics simulation approach.
    Alshawaf E; Hammad MM; Marafie SK; Ali H; Al-Mulla F; Abubaker J; Mohammad A
    Microb Pathog; 2022 Sep; 170():105701. PubMed ID: 35963279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (M
    Elgohary AM; Elfiky AA; Pereira F; Abd El-Aziz TM; Sobeh M; Arafa RK; El-Demerdash A
    Comput Biol Med; 2022 Aug; 147():105738. PubMed ID: 35777088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study.
    Alavi M; Mozafari MR; Ghaemi S; Ashengroph M; Hasanzadeh Davarani F; Mohammadabadi M
    Biomedicines; 2022 Nov; 10(12):. PubMed ID: 36551830
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the Cytotoxic and Antiviral Effects of Small Molecules Selected by In Silico Studies as Inhibitors of SARS-CoV-2 Cell Entry.
    Carvalhal F; Magalhães AC; Rebelo R; Palmeira A; Resende DISP; Durães F; Maia M; Xavier CPR; Pereira L; Sousa E; Correia-da-Silva M; Vasconcelos MH
    Molecules; 2023 Oct; 28(20):. PubMed ID: 37894682
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Chandra A; Chaudhary M; Qamar I; Singh N; Nain V
    J Biomol Struct Dyn; 2022 Sep; 40(14):6534-6544. PubMed ID: 33583328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.
    Santopolo S; Riccio A; Santoro MG
    Biochem Biophys Res Commun; 2021 Jan; 538():80-87. PubMed ID: 33303190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
    Nandi S; Roy H; Gummadi A; Saxena AK
    Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
    Stelitano D; Weisberg SP; Goldklang MP; Zhu Y; Bovier FT; Kalantarov GF; Greco G; Decimo D; Franci G; Cennamo M; Portella G; Galdiero M; Mathieu C; Horvat B; Trakht IN; Moscona A; Whitt MA; Porotto M
    mSphere; 2021 Aug; 6(4):e0057121. PubMed ID: 34319126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence.
    Riccio A; Santopolo S; Rossi A; Piacentini S; Rossignol JF; Santoro MG
    Cell Mol Life Sci; 2022 Apr; 79(5):227. PubMed ID: 35391601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2.
    Geromichalou EG; Geromichalos GD
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacophore-Based Virtual Screening, Quantum Mechanics Calculations, and Molecular Dynamics Simulation Approaches Identified Potential Natural Antiviral Drug Candidates against MERS-CoV S1-NTD.
    Bouback TA; Pokhrel S; Albeshri A; Aljohani AM; Samad A; Alam R; Hossen MS; Al-Ghamdi K; Talukder MEK; Ahammad F; Qadri I; Simal-Gandara J
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
    Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
    mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
    Ohishi T; Hishiki T; Baig MS; Rajpoot S; Saqib U; Takasaki T; Hara Y
    PLoS One; 2022; 17(7):e0271112. PubMed ID: 35830431
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.